Without FDA approval, the SVF treatments aren’t included in insurance, so a patient’s costs can run from $5,000 to $50,000, according to the report. A substantial danger, Taylor-Weiner said, is that sufferers who buy these providers may miss out on a chance for approved treatment. Sometimes patients are convinced to use these remedies instead of a far more effective, evidence-centered treatment, he said. Until these clinics are regulated, it’s rather a matter of purchaser beware, said Dr. David Katz, director of the Yale University Prevention Research Center in New Haven, Conn.Approximately 29 percent of patients had received an accepted disease-modifying therapy before research entry. Study completion prices were similar across research groups , with a mean amount of time in the study of 86.1, 84.4, 84.1, and 88.5 weeks in the placebo, twice-daily BG-12, thrice-daily BG-12, and glatiramer acetate groups, respectively. The price of study-drug discontinuation was higher in the placebo group than in the other groups , as was the proportion of sufferers who switched to substitute multiple sclerosis medications . Efficacy Clinical End Points The frequency of relapses of multiple sclerosis was significantly reduced by twice-daily and thrice-daily BG-12, with an adjusted annualized relapse rate at 2 years of 0.22 and 0.20, respectively, representing reductions relative to placebo of 44 percent and 51 percent .